Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

NCT00766363 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease
Central Nervous System Diseases

Interventions

DRUG: EVP-6124 (0.1 mg/day)
DRUG: EVP-6124 (0.3 mg/day)
DRUG: EVP-6124 (1.0 mg/day)
DRUG: Comparator: Placebo
DRUG: Donepezil
DRUG: Rivastigmine

Sponsor

FORUM Pharmaceuticals Inc

Collaborators

[object Object]